Henshaw Capital’s GSK GSK Stock Holding History

Henshaw Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,207	Closed	-$386K	–	345
2020 Q3	$386K	Buy	8,207 +4,189	+104%	+$210K	0.03%	187
2020 Q2	$205K	Buy	+4,018	New	+$206K	0.02%	294
2020 Q1	–	Sell	-4,018	Closed	-$236K	–	297
2019 Q4	$236K	Sell	4,018 -4,579	-53%	-$255K	0.02%	240
2019 Q3	$459K	Buy	8,597 +152	+2%	+$7.82K	0.04%	152
2019 Q2	$422K	Buy	8,445 +562	+7%	+$28.2K	0.04%	162
2019 Q1	$412K	Hold	7,883	–	–	0.04%	161
2018 Q4	$377K	Buy	+7,883	New	+$388K	0.04%	162
2018 Q2	–	Sell	-181,592	Closed	-$8.87M	–	307
2018 Q1	$8.87M	Hold	181,592	–	–	0.83%	39
2017 Q4	$8.05M	Hold	181,592	–	–	0.77%	42
2017 Q3	$9.22M	Buy	181,592 +1,074	+0.6%	+$54.5K	0.94%	38
2017 Q2	$9.73M	Buy	180,518 +48,518	+37%	+$2.59M	1.02%	38
2017 Q1	$6.96M	Buy	132,000 +56,000	+74%	+$2.84M	0.76%	42
2016 Q4	$3.66M	Buy	+76,000	New	+$3.75M	0.43%	50

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Henshaw Capital's GSK Position: Q4 2020 in Review

Henshaw Capital sold out of GSK (GSK) in Q4 2020, closing a stake of 8,207 shares — an estimated $386K sold.

Henshaw Capital first reported a position in GSK in Q4 2016 and held it in 13 quarters. The position peaked at $9.73M in Q2 2017. 819 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Henshaw Capital reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
Henshaw Capital sold 8,207 GSK shares in Q4 2020, an estimated $386K.
Henshaw Capital first reported a position in GSK in Q4 2016 and held it in 13 quarters.
Henshaw Capital's GSK position peaked at $9.73M in Q2 2017.
819 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Henshaw Capital's 13F filing for Q4 2020, filed 28 May 2026.